Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541335 | 0.93 | RAB9A (0.38) | TRPV1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2540184 | 0.91 | SMN1; SMN2 (0.36) | TRPV1SMN1; SMN2USP2LMNATSHR | |
| SCHEMBL2542845 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2USP2LMNATSHRCLK1 | |
| SCHEMBL2538982 | 0.87 | USP2 (0.40) | SMN1; SMN2USP2LMNATSHRCLK1 | |
| SCHEMBL2540214 | 0.87 | USP2 (0.40) | SMN1; SMN2USP2LMNATSHRCLK1 | |
| SCHEMBL2547871 | 0.86 | ALDH1A1 (0.44) | SMN1; SMN2USP2LMNATSHRCLK1 | |
| SCHEMBL2540218 | 0.86 | USP2 (0.41) | SMN1; SMN2USP2LMNATSHRCLK1 | |
| SCHEMBL2546284 | 0.85 | ALDH1A1 (0.42) | SMN1; SMN2USP2LMNATSHRCLK1 | |
| SCHEMBL2541766 | 0.85 | LMNA (0.36) | TRPV1SMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL2546149 | 0.85 | LMNA (0.39) | SMN1; SMN2USP2LMNATSHRCLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | TPMT, MET, PAICS | TRPV1 3503/4885SMN1; SMN2 2888/4885USP2 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.